EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

Rachael M Stone iD, Glenda Hoffecker iD, April Schultz iD, Brittney H Davis iD, Salma A Bargal iD, Amber L Beitelshees iD, Nihal El Rouby iD, Madeline Norris iD, Kevin J Rodriguez iD, Nita Limdi iD, Larisa H Cavallari iD, Craig R Lee iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Rachael M Stone und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Clopidogrel, Platelet Aggregation Inhibitors, Cerebrovascular Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles. While CYP2C19 ‐guided DAPT is well‐established for some cardiovascular indications, its use in neurovascular settings has remained limited until recently. This study characterized current implementation strategies for CYP2C19 ‐guided DAPT for neurovascular indications across institutions in the Pharmacogenomics Global Research Network Implementation Working Group. A REDCap survey was distributed to 54 institutions targeting those currently utilizing or planning to implement CYP2C19 testing to guide clopidogrel use for neurovascular indications. The survey collected data on implementation status, workflows, testing logistics, clinical decision support (CDS), and guideline concordance. Fifteen institutions met inclusion criteria; 80% were in the United States and 87% were academic centers. CYP2C19 testing was used for neurovascular indications at 12 sites, most commonly for AIS, intracranial aneurysm repair, and intracranial stenting. Implementation was often built on infrastructure previously established for cardiovascular indications. Most sites used multigene panels, offered testing in both inpatient and outpatient settings, and returned results within 7 days. Eighty percent of sites provided CDS to support application of results. All sites recommended an alternative P2Y12 inhibitor (e.g., ticagrelor) for poor metabolizers, and most did for intermediate metabolizers. CYP2C19 ‐guided antiplatelet therapy for neurovascular indications is expanding, with many implementations leveraging preexisting infrastructure from cardiovascular settings. Broader adoption and outcome‐focused research are needed to optimize the clinical utility of genotype‐guided DAPT in neurovascular care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19ClopidogrelPlatelet Aggregation InhibitorsCerebrovascular DisordersHumansPharmacogenomic TestingDual Anti-Platelet TherapyGenotypeAspirinSurveys and Questionnaires

Substanzen

Cytochrome P-450 CYP2C19ClopidogrelCYP2C19 protein, humanPlatelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • University of Virginia, Charlottesville, Virginia, USA.
  • University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Sanford Imagenetics, Sanford Health, Sioux Falls, South Dakota, USA.
  • University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • University of Maryland, Baltimore, Maryland, USA.
  • University of Cincinnati, Cincinnati, Ohio, USA.

ORCID-Profile: Rachael M Stone, Glenda Hoffecker, April Schultz, Brittney H Davis, Salma A Bargal, Amber L Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J Rodriguez, Nita Limdi, Larisa H Cavallari, Craig R Lee

Zitieren

APA

Stone, R. M., Hoffecker, G., Schultz, A., Davis, B. H., Bargal, S. A., Beitelshees, A. L., El Rouby, N., Norris, M., Rodriguez, K. J., Limdi, N., Cavallari, L. H., & Lee, C. R. (2026). CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70402

Vancouver

Stone RM, Hoffecker G, Schultz A, Davis BH, Bargal SA, Beitelshees AL, et al. CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70402

BibTeX
@article{Stone2026,
  author = {Stone, Rachael M and Hoffecker, Glenda and Schultz, April and Davis, Brittney H and Bargal, Salma A and Beitelshees, Amber L and El Rouby, Nihal and Norris, Madeline and Rodriguez, Kevin J and Limdi, Nita and Cavallari, Larisa H and Lee, Craig R},
  title = {CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70402}
}
Kostenlos starten →